ACC 2024: Insights on Advancements in Lipid Management and Atherosclerosis Prevention

Erin D. Michos, MD, MHS

April 12, 2024

Erin D. Michos, MD, MHS, offers insights on trials that sought to advance lipid management and atherosclerosis prevention at ACC 2024. The VICTORION-INITIATE trial showed inclisiran's efficacy, reducing LDL by 60% in atherosclerosis patients while the TACTiC trial demonstrated the efficacy of a technology-assisted approach in qualifying patients for statin therapy, offering a novel pathway to enhance access and adherence.

Additionally, ApoC-III inhibitors showed reductions in triglycerides in patients, with olezarsen in the BALANCE trial and the BRIDGE-TIMI 73a trial, and with plozasiran in the SHASTA-2 trial.

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Cite this: ACC 2024: Insights on Advancements in Lipid Management and Atherosclerosis Prevention - Medscape - Apr 12, 2024.

Comments

Commenting is limited to medical professionals. To comment please Log-in.

Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.